poolbeg Pharma |

Poolbeg Pharma #POLB – Article

The @McKinsey’s #biotech #investment themes article highlights “insufficient number of high-quality data”a limitation to AI #drugdiscovery #POLB‘s #AI programmes have access the world’s largest data & #biobank of high-dimensional #disease progression data https://twitter.com/PoolbegPharma/status/1536593979264868352

Open Orphan #ORPH – Final results Reveal Record revenues and EBITDA-profitability accompanied by significant operational progress

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its audited final results for the 12 months ended 31 December 2021. Financial highlights · Record revenues of £39.0m (2020: £22.2m) achieved representing 76% growth · […]

Alan Green covers Amaroq Minerals #AEXG and Poolbeg Pharma #POLB on this week’s Stockbox Research Talks

Poolbeg Pharma #POLB to engage with key international stakeholders at European Melioidosis Congress as it develops an intramuscular Melioidosis vaccine candidate

11 May 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, is participating in the European Melioidosis Congress (EMC) 2022, due to take place 16 May 2022 – 18 May 2022 in Graz, Austria, as it develops a […]

Poolbeg Pharma #POLB presenting at LSX Leaders event

Today Poolbeg Pharma #POLB will be attending the LSX Leaders event & CEO Jeremy Skillington will be presenting the Poolbeg Pharma story, including how we are aspiring to become a one-stop-shop for Big Pharma seeking mid-stage products to license or acquire.

Poolbeg Pharma #POLB – Results of the proposal to purchase shares from Distribution in Specie shareholders

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces the results of the proposal from a number of New Investors to purchase shares from distribution in specie shareholders ahead of the end of the lock-up period. As published via […]

Open Orphan #ORPH – Proposal to purchase Poolbeg Pharma shares from distribution in specie shareholders

Open Orphan (ORPH) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement dated 11 April 2022 from Poolbeg Pharma plc (“Poolbeg”), regarding a number of new investors (“New Investors”) having expressed interest in acquiring up to £1.6m of […]

Poolbeg Pharma #POLB – POLB 001 Clinical Development – Clinical Trial Agreement Signed

31 March, 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’) announces that it has signed a Clinical Trial Agreement with the Centre for Human Drug Research (CHDR) in the Netherlands for the completion of a bacterial lipopolysaccharide (‘LPS’) human challenge study of POLB 001, which is due to commence in June […]

Poolbeg Pharma #POLB commences trading on OTCQB Market in the United States

30 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that trading in the Company’s Ordinary Shares of nominal value of £0.02 each (“Ordinary Shares”) will commence today on the OTCQB Venture Market in the United States. The […]

Poolbeg Pharma #POLB – 2021 Annual Report and 2022 AGM Notice

Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model , announces that its Annual Report and Accounts for the period ended 31 December 2021, a notice of the Annual General Meeting (“AGM”) 2022 and voting proxy form have been posted to shareholders. […]